BioPharmSignal logoBioPharmSignal

Biotech News

Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule

Alzamend Neuro (ALZN)Alzamend NeuroFinancing

ALZN (ALZN) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is alzn.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

ALZNAlzamend Neuro2026-08-04 12:00 EST

Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending

PASGPassage Bio2026-06-24 20:05 EST

Passage Bio and Remix Therapeutics Announce Merger Agreement

ALZNAlzamend Neuro2026-08-20 12:00 EST

Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC

NGENNervGen Pharma2026-05-22 03:27 EST

NervGen Announces Pricing of US$60.0 Million Public Offering of Securities

ANVSAnnovis Bio2026-05-20 12:00 EST

Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants

TSHATaysha Gene Therapies2026-06-25 02:34 EST

Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

TSHATaysha Gene Therapies2026-06-24 20:01 EST

Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

NGENNervGen Pharma2026-05-21 20:01 EST

NervGen Announces Proposed Public Offering of Securities

View all latest news

Alzamend Neuro

Alzamend Neuro is a neuroscience company focused on Alzheimer's disease and other neuropsychiatric disorders. Its story is built around high-risk CNS development and novel treatment approaches.

Recent company news

ALZNAlzamend Neuro2026-08-20 12:00 EST

Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC

ALZNAlzamend Neuro2026-08-18 12:00 EST

Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain

ALZNAlzamend Neuro2026-08-04 12:00 EST

Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending

ALZNAlzamend Neuro2026-04-07 12:00 EST

Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital

ALZNAlzamend Neuro2026-03-26 12:00 EST

Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions

Stock data

Close
1.56 USD
Market cap
4.34M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States